Astragalus polysaccharides improve adjuvant chemotherapy-induced fatigue for patients with early breast cancer.
Astragalus polysaccharides
Adjuvant chemotherapy
Breast cancer
Cancer-related fatigue
Chemotherapy-related fatigue
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
28
04
2024
accepted:
15
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
This study aimed to evaluate the effect of Astragalus polysaccharides (PG2) on reducing chemotherapy-induced fatigue (CIF) and toxicity, thereby encouraging compliance to chemotherapy. This was a randomized, placebo-controlled, phase 2 study. Patients with stage II/III early breast cancer planning to undergo adjuvant anthracycline-based chemotherapy were randomly assigned to receive PG2 500 mg or placebo on days 1, 3, and 8 every 21 days. The fatigue global score (FGS) was assessed using the brief fatigue inventory (BFI)-Taiwan. The Breast Cancer-Specific Module of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaires-Core30 evaluated the health-related quality of life during the first four cycles of adjuvant chemotherapy. Overall, 66 eligible patients were equally randomized into the PG2 and placebo groups between March 01, 2018, and March 09, 2021. The mean change in the FGS and fatigue intensity did not significantly differ between both groups. However, the FGS and fatigue intensity were less aggravated in the first four cycles in the premenopausal-PG2 group than in the placebo group. Our study concluded PG2 combined with adjuvant chemotherapy can reduce CIF, insomnia, the negative effect on future perspectives, and improve global health status, especially for premenopausal patients with breast cancer. Trial registration number: NCT03314805 registered on 19/10/2017.
Identifiants
pubmed: 39465324
doi: 10.1038/s41598-024-76627-z
pii: 10.1038/s41598-024-76627-z
doi:
Substances chimiques
Polysaccharides
0
Banques de données
ClinicalTrials.gov
['NCT03314805']
Types de publication
Journal Article
Randomized Controlled Trial
Clinical Trial, Phase II
Langues
eng
Sous-ensembles de citation
IM
Pagination
25690Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
Bines, J., Earl, H., Buzaid, A. C. & Saad, E. D. Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter? Ann. Oncol. 25, 1079–1085 (2014).
doi: 10.1093/annonc/mdu007
pubmed: 24625452
Rau, K. M. et al. A nationwide survey of fatigue in cancer patients in Taiwan: an unmet need. Jpn J. Clin. Oncol. 50, 693–700 (2020).
doi: 10.1093/jjco/hyaa038
pubmed: 32303764
pmcid: 7284537
Gluz, O. et al. Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial. Ann. Oncol. 34, 531–542 (2023).
doi: 10.1016/j.annonc.2023.04.002
pubmed: 37062416
Yuan, P. et al. Effect of epirubicin plus paclitaxel vs epirubicin and cyclophosphamide followed by paclitaxel on disease-free survival among patients with operable ERBB2-negative and lymph node-positive breast cancer: a randomized clinical trial. JAMA Netw. Open. 6, e230122 (2023).
doi: 10.1001/jamanetworkopen.2023.0122
pubmed: 36826820
pmcid: 9958529
Gianni, L. et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 25–32 (2012).
doi: 10.1016/S1470-2045(11)70336-9
pubmed: 22153890
Slamon, D. et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl. J. Med. 365, 1273–1283 (2011).
doi: 10.1056/NEJMoa0910383
pubmed: 21991949
pmcid: 3268553
Mittendorf, E. A. et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 396, 1090–1100 (2020).
doi: 10.1016/S0140-6736(20)31953-X
pubmed: 32966830
Schmid, P. et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl. J. Med. 386, 556–567 (2022).
doi: 10.1056/NEJMoa2112651
pubmed: 35139274
Chen, H. W. et al. A novel infusible botanically-derived drug, PG2, for cancer-related fatigue: a phase II double-blind, randomized placebo-controlled study. Clin. Invest. Med. 35, E1–E11 (2012).
doi: 10.25011/cim.v35i1.16100
pubmed: 22309959
Wang, C. H. et al. Karnofsky Performance Status as a predictive factor for cancer-related fatigue treatment with Astragalus polysaccharides (PG2) injection-a double blind, multi-center, randomized phase IV study. Cancers (Basel). 11, 128 (2019).
doi: 10.3390/cancers11020128
pubmed: 30678249
Du, Y., Wan, H., Huang, P., Yang, J. & He, Y. A critical review of Astragalus polysaccharides: from therapeutic mechanisms to pharmaceutics. Biomed. Pharmacother. 147, 112654 (2022).
doi: 10.1016/j.biopha.2022.112654
pubmed: 35086031
Tsao, S. M., Wu, T. C., Chen, J., Chang, F. & Tsao, T. Astragalus polysaccharide injection (PG2) normalizes the neutrophil-to-lymphocyte ratio in patients with advanced lung cancer receiving immunotherapy. Integr. Cancer Ther. 20, 1534735421995256 (2021).
doi: 10.1177/1534735421995256
pubmed: 33583212
pmcid: 7890706
Lin, C. C. et al. Validation of the Taiwanese version of the brief fatigue inventory. J. Pain Symptom Manage. 32, 52–59 (2006).
doi: 10.1016/j.jpainsymman.2005.12.019
pubmed: 16824985
Chie, W. C., Chang, K. J., Huang, C. S. & Kuo, W. H. Quality of Life of Breast Cancer Patients in Taiwan: Validation of the Taiwan Chinese version of the EORTC QLQ-C30 and EORTC QLQ-BR23. Psychooncology. 12, 729–735 (2003).